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Summary 
Multisystem deterioration occurs mainly in older individuals and may be related to 
physiological tissue degeneration. However, genetic predisposition may be unmasked 
by inappropriate functional and structural system deficiencies. McLeod Syndrome 
(MLS) is a rare, multisystem disease which is X-chromosomal inherited and belongs to 
the Neuroacanthocytosis Syndromes (NAS). The main clinical manifestations contain 
progressive neuro-psychiatric and cognitive deterioration, choreatic movement 
disorder, as well as myopathy, sensorymotor axonal neuropathy and cardiomyopathy. 
In addition, MLS patients have red blood cell abnormalities including immune-
hematological, morphological and functional impairments of red blood cells.  In large 
deletions, contiguous gene syndrome may arise, including Duchenne muscular 
dystrophia, cellular immunodeficiency or retinitis pigmentosa. Hematological 
abnormalities such as blood group abnormalities in Kell- and XK blood group system, 
formation of anti-public red blood cell alloantibodies, acanthocytosis and elevated 
creatinine phosphokinase may precede clinical disease manifestation for decades and 
provide tools for early diagnosis. Patients with unexplained neuro-muscular 
deterioration and/or neuro-psychological pathologies accompanied with hematological 
abnormalities should be investigated for MLS.     
 
  
McLeod Syndrom (MLS) is part of the Neuroacanthocytosis Syndromes (NAS) 
NAS are defined as progressive neurodegenerative diseases affecting mainly basal 
ganglia including nucleus caudatus and putamen in association with red blood cell 
acanthocytosis. Additional hematological abnormalities e.g. morphological, functional 
and serological aberrations of red blood cells (RBC) are part of disease defining clinical 
features.1-3. Four different diseases with overlapping clinical manifestations account 
for the NA syndromes: Choreoacanthocytosis (ChAc) and the McLeod syndrome (MLS) 
constitute the core NAS and are caused by mutations of the VPS13A gene on 
chromosome 9q21 and the XK gene on Xp21.1, respectively. The more rare diseases 
such as Huntington-like2 disease (HDL2) and the pantothenate kinase 2 disease 
(PKAN) complete the group of NAS. Affected genes and proteins, mechanism of 
inheritance and clinical as well as laboratory phenotypes are summarized in table 1.  
Usually, the MLS is diagnosed in patients with progressive neuro-psychiatric 
deficiencies and having excluded other pathologies such as Huntington´s disease, 
Tourette’s syndrome and familial hemolytic anemia. The clinical picture reflects a 
neuro-hematological disorder4 where the subtle hematological findings may precede 
the neurological deficiencies for decades and remain unrecognized until neuro-
psychiatric alterations prompt invasive assessment. The patients suffer on premature 
dementia, intellectual and cognitive impairment, depression, personality changes, 
social retraction and in some cases they may suffer of movement disorders such as 
choreatic movement disorder and dystonia as well as generalized epileptic 
seizures1,2,5-12. In all MLS patients examined up to date creatinine phosphokinase 
(CPK) is elevated, without signs of acute myocardial and muscular cell necrosis or 
renal insufficiency. The diagnostic key feature is the prototypic McLeod blood group 
phenotype comprising weakened or absent Kell blood group antigens and negativity 
for the Kx antigen on the red blood cell membrane. This blood group abnormality is 
highly specific for MLS and separates the disease from other NAS. In many patients 
with MLS the blood group peculiarity goes along with acanthocytosis of variable 
degree and compensated hemolytic anemia. However, several individuals have been 
described with exclusive McLeod RBC phenotype without other hematological, neuro-
psychiatric and neuro-muscular symptoms13,14. Mostly, these cases are recognized 
when being blood group phenotyped for KEL antigens while serving as blood donors. 
Infact, the first case discovered with the prototypic RBC phenotype was the healthy 
blood donor Mr. McLeod, who engaged into blood donation as a dentist student and 
was diagnosed with “a new phenotype (McLeod) in the Kell blood group system”15 
because of weakened expression of several Kell antigens as compared to his parents. 
  
Peculiarity of blood group antigens on McLeod erythrocytes 
The MLS is the only NAS with distinct blood group abnormality affecting the KEL (ISBT 
06) as well as the XK (ISBT 019) blood group system. The Kell glycoprotein (CD238) 
is a type II single-pass transmembrane red blood cell protein containing 732 
aminoacids and functions as an endopeptidase which cleaves big-endothelin3 into the 
active endothelin3, that acts as a potent vasoconstrictor16,17. It expresses at least 35 
recognized blood group antigens, including 5 antithetical pairs exerting clinical 
relevance18. From these, the K/k pair (Kell/Cellano) is the most important one19. The 
single aminoacid exchange of methionine replacing threonine at position 193 
(Met193Thr) eliminates a N-glycosylation site of the Kell protein constituting the K 
(KEL1) and k (KEL2) epitopes, respectively. Alloantibodies against K and k may cause 
severe hemolytic transfusion reactions as well as live-threatening morbus hemolyticus 
neonatorum19,20.  
The XK protein, encoded by the XK gene at Xp21.1 is a 444 aminoacid multipass red 
blood cell membrane peptide, forming a heterodimer with the Kell glycoprotein and 
expresses the single blood group antigen Kx21,22. The antigen Kx is located at the fifth 
extracellular loop of the XK peptide in close proximity to the disulfide bond XKCys347-
KellCys72, covalently linking and stabilizing the Kell-XK heterodimer22. In most 
ethnicities, the frequency of the Kx antigen is >99% and may therefore be considered 
as “the public Kx phenotype”19. Individuals with the McLeod phenotype, 
characteristically lack the Kx antigen, which is due to a complete absence or a 
drastically shortened XK protein and may rise anti-public red blood cell antibodies 
such as anti-Kx and anti-Km upon immunizing events, such as transfusion. These 
alloantibodies will react with most of the homologous blood donations and may 
therefore generate substantial problems in the supplementation with correctly 
matched, e.g. Kx negative blood4,13,23. In Kx negative individuals, the observed 
weakened agglutination of Kell antigens serves as surrogate for the McLeod phenotype 
and needs to be distinguished from a modified Kell antigen expression in Kmod and 
Knull phenotypes. These, equally rare variants of KEL alleles lead to modified Kell 
protein expression24,25 without molecular, phenotypic and clinical signs of MLS. The 
red blood cells of Kmod and Knull phenotypes express the Kx antigen24,26,27 and will 
therefore not develop anti-public antibodies in the Kx blood group system. 
Genetic defects at Xp21.1 lead to the absence or truncation of the XK protein causing 
both, the reduced or complete absence of the Kell antigen in the erythrocyte 
membrane, as well as the absence of the Kx blood group antigen (Kx-)5. At least 29 
different  mutations at Xp21.1 are recognized as molecular mechanism for the Kx- 
phenotype5,18. These are missense and stop mutations anywhere in the three exons of 
the coding sequence as well as splice site and insertion/deletion mutations leading to 
erroneous translation and transcription of the gene, respectively5. In cases of large 
deletional defects, neighbour genes of XK may also be affected and give rise to the 
“contiguous gene syndrome”28, of which the clinical phenotype is dominated by the 
co-affected gene(s)29. Most important are deletions affecting DMD, a gene located 
telomeric to XK, leading to Duchenne muscular dystrophy28 or deletions affecting the 
centromeric CYBB gene, leading to X-linked granulomatous disease (X-CGD)30,31. 
Figure 1 gives an overview on some of the molecular defects at Xp21.1 and there 
consequences for the XK protein. 
 
Distinct morphology of McLeod erythrocytes 
Patients suffering on MLS or ChAc usually present with various degree of 
acanthocytosis in circulating blood, which may be visualized by light microscopy of a 
blood smear. The abnormally shaped RBCs (acanthocytes) are characterized by few 
irregular membrane protrusions32. They are different from echinocytes which show 
many, more regular and shorter membrane bulges. However, although the 
morphological variants are distinct, these RBC abnormalities are interchangeable and 
in most cases acanthocytes are accompanied by echinocytes33. Since the lipid 
composition of altered RBC is normal, the acanthocytic shape change results from 
impaired interaction of the membrane multiprotein complexes (MMPC) with the 
cytoskeleton of red blood cell33. The major RBC anion exchanger protein, band 3 (B3), 
one of the most abundant membrane protein, is organized either as a tetrameric B3-
ankyrin complex, a dimeric B3-protein 4.1R complex (also called “junctional complex”) 
and as a free B3 protein34,35. The B3 multimeric entities are attached to various other 
transmembrane proteins such as glycophorin A and C, Rh protein/Rh associated 
glycoprotein (RhAG), Kell, XK and Duffy proteins as well as CD47 and Landstein-
Wiener (LW) glycoproteins and thereby constitute the MMPC. The MMPC interact with 
the RBC cytoskeleton by recruiting linker proteins such as protein 4.2/ankyrin (ankyrin 
complex) and protein 4.1R/adducin (4.1R complex)36-38. The MMPC-cytoskeleton 
network controls the RBC discocytic shape and determines RBC deformability, 
rheological, adhesive and functional properties37,39,40. Deficiencies in one or several 
proteins of MMPC impairing the MMPC-cytoskeleton interaction were found to cause 
inherited RBC membranopathies such as hereditary eliptocytosis, ovalocytosis, 
stomatocytosis and spherocytosis37,41-49. Moreover, the cytoplasmic part of B3 as well 
as of other attached membrane proteins control a variety of metabolic pathways in 
RBC by binding to aldolases, kinases, oxidases and phosphatases50-58.  
However, not only deficiencies or dysfunction of RBC membrane proteins may lead to 
acanthocytosis. Also, hereditary disorders of lipid metabolism such as apolipoprotein A 
and vitamin E deficiency59,60 as well as a number of acquired conditions such as acute 
and chronic anemia, hepatitis, alcoholic liver cirrhosis, hypopituitarism, 
hypothyreoidism, malabsorption syndromes and malnutrition may be associated with 
acanthocytic shape change of RBC61.  
Acanthocytic RBCs are a typical finding in NAS especially in patients with MLS and 
ChAc. However, the finding is neither specific nor sensitive enough for clinical 
diagnosis13,14. Moreover, the in vitro diagnosis of acanthocytes is technically 
demanding and prone of false positive testing62. Therefore, Storch et al. suggested a 
modified technique to assess peripheral blood smears for acanthocytes. According to 
Storch et al., quantification of acanthocytes needs to be done using wet smear of  
diluted blood sample and by applying dark filed microscopy62. Due to technical 
demanding procedure and the low disease specificity of acanthocytes, this test has 
lost its diagnostic power. Nevertheless, functional impairment of transmembrane ion 
transport58,63-65, impaired formation of endovesicles by acanthocytes in NAS66 and the 
findings by DeFranceschi et al who described 14 kinases constituting a mutual 
phospho-tyrosine sub-network in acanthocytes of NAS51 suggest common pathways 
for acanthocyte formation and neurodegeneration in NAS. Therefore, acanthocytes of 
MLS may provide an easy accessable substrate to be investigated for patho-
mechanism of disease and may paste new avenues of treatment options for patients 
suffering on NAS.  
 
MLS is a multisystem disorder 
Although the genetic alteration in MLS was precisely located at Xp21.167 the 
genotype-phenotype correlation is weak and most mutation carriers are discovered 
while being assessed for a wide spectrum of subtle to severe central nervous system  
or neuromuscular affection occurring together with pathological changes of red blood 
cells (acanthocytosis, coombs-negative, hemolytic anemia)1-3,68. The molecular 
characterization of underlying genetic defects in NAS allow unambiguous distinction 
between the four different entities of NAS (Table 1). Molecular defect identification has 
therefore become the key tool for diagnosis1,69. In MLS, the disorder is caused by the 
affection of the XK protein, which is expressed ubiquitously in body tissues70 and most 
likely functions as a membrane transporter71,72 with so far not precisely defined 
substrate. In the RBC membrane the XK protein is co-expressed with the Kell protein 
and forms a heterodimer22,27,70,73. In contrast, non-hematopoietic cells express the XK 
protein independently of the Kell protein which may not even be present70. Therefore, 
XK may act as a universal gatekeeper by direct or indirect control of substrate 
exchange between different subcellular compartments70,72. Several groups have 
shown, that in the absence of XK or other RBC membrane proteins, the RBC shape 
and transmembrane ion transport may be severely altered. Active ion transport 
channels including the Ca2+ dependent K+ transport (Gardos channel) as well as the 
transporters of Mg2+,Cl-, SO4- and other ions are negatively affected58,63,65,66,74. 
Especially, the proper function of Gardos channel is pivotal for the integrity and 
function of RBCs75-78. Gardos channels are ubiquitously expressed in body tissue79 and 
their functionality may depend on intact XK protein. In line with this assumption, 
disruption of XK may therefore lead to multisystem deficiencies by impairment of 
Gardos functionality which could explain the chef affected cardiac and neuronal tissues 
in MLS79-83 (see Table 1).   
 
Molecular MLS Assessment 
 
As detailed earlier, the NAS are monoallelic deficiency syndromes, perfectly suited for 
molecular defect analysis. The genetic defects of MLS always involve XK, the gene 
encoding the XK protein and its Kx antigen, which is located at Xp21.1. The genetic 
lesions may be point mutations leading to amino acid exchanges and stop codons, 
splice site mutations and small insertional and deletional aberrations (indels), as well 
as large X-chromosomal deletions involving up to approximatively 5 Mio bp, as 
reported as of yet. A listing of all currently known XK-null alleles, e.g. XK*N01 to 
XK*N29, may be retrieved from the homepage of the ISBT terminology committee18. 
The mode of inheritance of MLS is X-chromosomal recessive, implying carrier status 
with no, or abrogated clinical disease manifestation in mothers, sisters and daughters 
of affected males. To exclude a disease caused by a molecular defect at Xp21.1, we 
designed a systematic approach to investigate the regions, telomeric and centromeric 
to XK for the unique identification of contiguous gene defects. In brief, the X-
chromosome is investigated in between OTC (Ornithine Carbamoyltransferase at 
Xp11.4, OMIM*300461) and DMD (Duchenne Muscular Dystrophy, Dystrophin 1 at 
Xp21.2, OMIM*300377), by 36 equally distanced positional PCRs also co-amplifying 
sequences of the Human Growth Hormone 1 (GH1 at 17q23.3, OMIM*139250), which 
serve as positive amplification controls. The X-chromosomal distance investigated by 
this approach covers more than 8.8 Mio basepairs (bp) in total and includes XK, 0.7 
Mio bps from its centromeric end (McLeod Syndrome associated XK at Xp21.1, 
OMIM*314850), as well as CYBB (Cytochrome b(-245) subunit associated with X-CGD 
at Xp11.4, OMIM*300481) and RPGR (Retinitis Pigmentosa GTPase Regulator at 
Xp11.4, OMIM*312610). In case of large X-chromosomal deletions, certain positional 
PCRs will fail to amplify. The indicated gap is then narrowed down by additional 
positional PCRs until the breakpoint of the deletion may be bridged by one single PCR. 
Consequently, this case specific PCR product is then sequenced and allows for the 
exact definition of the breakpoint position, and may itself already be used as highly 
accurate diagnostic tool for the detection of a carrier status in mothers, sisters and 
daughters of affected males. In case, no large X-chromosomal deletion is observed, all 
three XK exons, also including some sequences of the promoter and at least 50 bp of 
each flanking intron will be sequenced to reveal point mutations within the gene, 
potentially causative of an XK inactivating effect. The effect of such point mutations 
may be clearly evident, e.g. when nonsense mutations lead to the creation of stop 
codons in the predicted XK peptide, or be less informative and of questionable 
meaning, e.g. when exchanged amino acids share in between no, and up to similar 
physiochemical properties, then called “radical” and “conservative missense 
mutations”, respectively. Using this approach we were able to describe five intragenic 
XK mutants, with only one of them already known and listed as XK*N.20 by the ISBT 
terminology committee18, the others, with as yet undescribed nonsense (n=1), frame 
shift (n=1) and radical missense mutation (n=1) and two large X-chromosomal 
deletions, respectively. All carriers had different MLS phenotypes including 
neuropsychiatric disorder associated with hereditary sudden death syndrome, severe 
choreatic movement disorder and X-linked CGD, in one case (manuscript in 
preparation).       
 
Clinically guided MLS diagnosis 
Most of the MLS mutations described so far were discovered in patients being 
investigated for neuro-psychiatric or choreatic movement disorders or in cases with 
immune deficiency syndromes5. Normally, the patients suffer of unspecific neuro-
psychiatric symptoms for years without having assigned clear diagnosis. Sometimes, 
MLS is diagnosed in asymptomatic mutation carriers, most often when routinely 
phenotyped for KEL antigens while serving as blood donors13-15. These blood donors 
may develop clinical MLS later on and available data indicate a high penetrance of the 
disorder with a possible onset in the sixth and seventh decade84. However, in patients 
with unexplained neuro-psychiatric problems or choreatic movement disorders with 
onset in the third or fourth decade it might be important to exclude MLS as the 
underlying disease causing condition. The findings may have important implications 
for the usually male patient as well as for his family members. Although the disease 
progression cannot be stopped, early supportive measures such as seizure protection, 
psychiatric treatment as well as prevention of mutilating involuntary movements may 
provide desired palliation of disease associated disabilities. Importantly, early 
recognition of orofacial dystonia may be pivotal to prevent feeding impairment and 
secondary wasting disease85. Also, the recognition of private blood type (Kx-) is 
crucial when it comes to transfusion support. By timely searching for Kx- blood donors 
from international donor registries or alternatively, by use of cryopreserved 
autologous blood units the formation of anti-public antibodies can be prevented23. 
Finally, cardiac complications such as fatal arrhythmia may be prevented by 
implantation of a cardiac pacemaker86. 
For genetic counselling of MLS patient’s family members, it is important to identify the 
exact genetic defect which can then be followed for segregation in the relatives of the 
patient. Finally, in X-linked CGD patients, the exclusion of mutations at Xp21.1 is 
pivotal in planning and exertion of CGD treatment which often includes stem cell 
transplantation and transfusion support87,88. 
We established an algorithm to comprehensively assess patient’s samples for 
suspected McLeod mutations (Figure 2). Firstly, the patient’s RBCs are examined for 
expression of the Kx antigen as well as several antithetical Kell antigens (e.g. K, k, 
Kpb) by conventional serology techniques. It is important to emphasize that IgG 
coating of patient’s RBCs needs to be excluded by negative direct antiglobuline test in 
order to validate serological antigen determination. Also, genetic investigation for 
inherited Kell antigens by commercial genotyping kits helps to confirm serological 
findings. In case the Kx antigen is absent and the inherited Kell antigens show 
weakened or missing expression, the McLeod red cell phenotype is proven. In such 
cases, the blood smear is assessed for the presence of acanthocytes and the extracted 
genomic DNA will be searched for disease causing mutations (see above). Identified 
mutations will then be used to design a molecular protocol to follow the segregation 
the of disease specific mutation in consanguineous family members. In order to 
complete an individual McLeod assessment, we further recommend to perform an 
expression study of the KEL protein by flowcytometry as described earlier13. 
Flowcytometric investigation of KEL protein expression by using commercially 
available anti-Kell antibodies (e.g. BRIC18, BRIC68, BRIC203, provided by IBGRL, 
Bristol/UK) allows for a quantification of the circulating McLeod RBCs admixed to 
normal RBCs. Double RBC populations with normal and depressed KEL protein 
expression is a typical finding in female McLeod carriers4,7. All individuals with 
confirmed McLeod RBC phenotype need to be assessed for the presence of red blood 
cell alloantibodies, since anti-public alloantibodies may have substantial consequences 
for transfusion support of MLS patients.   
 
Conclusion 
MLS is a rare multisystem disease which affects mainly male adults. Neuro-
psychiatric, neuromuscular, cardial and hematologic affection dominate the clinical 
picture and may vary substantially in individual patients. Early diagnosis in patients 
with suggestive clinical symptoms is crucial for guiding the patient’s management in 
order to prevent cardial and hematologic sequelae and to palliate clinical and social 
consequences of disease. Diagnostic cornerstones are red blood cell phenotyping in 
the XK- and KEL system, appropriate molecular analysis of underlying genetic defect 
and quantification of circulating acanthocytes. The molecular mutation analysis also 
provides insights into multi gene defects (contiguous gene syndrome) which is most 
important in cases with juvenile X-linked granulomatous disease, retinitis pigmentosa 
and Duchenne muscular dystrophy.   
   
 
 
 
 
 
  
Legends 
 
Table 1:  
Genetic and somatic deficiencies in NA syndromes. Various genetic defects with 
distinct inheritance and overlapping clinical manifestation constitute the NA 
syndromes. Adapted from Jung et al2  
ChAc: Choreoacanthocytosis, MLS: McLeod Syndrome, HDL2: Huntigton-like2 
Syndrome, PKAN: Pantothenatekinase 2 Disease 
 
 
  
Figure 1:  
The XK gene with its three exons and the corresponding red blood cell multipass 
membrane protein XK are shown. All three exons may be affected by stop and 
missense mutations leading to shortened or missing protein at the red cell surface. 
Also splice site mutation as well as partial and complete gene deletion mutations may 
cause absence of XK protein. Whole XK gene deletions extending to telomeric and 
centromeric coding regions may lead to the contiguous gene syndrome. 
X: Marks premature termination of XK protein assembly due to stop codon 
Figure 2: 
Figure 2 delineates the systematic analysis of patient samples suspected for the 
presence of a McLeod mutation. The assessment always starts with the serological 
evaluation for KEL and Kx antigen expression, which are expected to be either 
negative or weakened. The antigen expression pattern needs to be validated by 
negative direct antiglobuline test. In case of positive DAT, the antigens might be 
determined false positive. Kx antigen expression pattern will then guide further 
evaluation performed. If Kx is negative, an assumed molecular defect directly encoded 
by the XK gene itself, or alternatively a large deletion affecting the expanded XK locus 
at Xp21.1 is checked for. Respective X-chromosomal mutations may then establish 
the diagnosis of McLeod syndrome and also explain the  secondary weakend Kell 
antigen expression. If Kx reacts positive, the MLS is excluded and other reasons for 
weakened KEL expression might be checked for (Kmod, KNull, Kpa+). In MLS, further 
diagnostic steps may be taken, e.g. detailed FACS analysis of weakened Kell antigen 
expression, or a microscopic investigation for the presence of acanthocytes. 
DAT: Direct Antiglobuline Test  
FACS: Fluorescence Activated Cell Sorting   
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Table 1 
Disorder 
Phenotype  
ChAc MLS HDL2 PKAN 
     
Gene/Chromosome VPS13A/9q21 XK/Xp21.1 JPH3/16q24.3 PANK2/20p13 
Protein Chorein XK protein Junctophilin-3 Pantothenate kinase 2 
Inheritance autosomal/recessive X-linked/recessive autosomal/dominant autosomal/recessive 
Hemolytic anemia none yes (not always) none none 
Acanthocytes +++ ++ +/- +/- 
Serum CK increased increased normal normal 
Neuroimaging 
abnormalities 
striatal striatal striatal/cortical striatal 
“Eye of the tiger” 
Age of onset 20 - 30 25 - 60 20 - 40 < 16 
Chorea +++ +++ +++ +++ 
Other movement 
Disorders 
dystonia 
lip biting 
parkinsonism 
vocalization dystonia, 
parkinsonism 
dystonia 
parkinsonism 
spasticity 
Seizures yes yes none none 
Neuromuscular 
defects 
areflexia  
atrophy 
areflexia 
atrophy 
none none 
Cardiac affection none arrhythmias 
cardiomyopathia 
sudden cardiac 
death 
none none 
  
